NV-387是针对马托克斯、天花和麻疹的一种广泛频谱抗病毒药物,纳米病毒药物寻求成为NV-387的无主药物地位。 NanoViricides seeks orphan drug status for NV-387, a broad-spectrum antiviral targeting MPox, smallpox, and measles.

Nano Viricides已聘请监管顾问Timothy Cote博士的律所为抗病毒候选者NV-387寻求孤儿药品地位, NanoViricides has hired regulatory consultant Dr. Timothy Cote’s firm to pursue orphan drug status for its antiviral candidate NV-387, targeting MPox, smallpox, and measles—diseases deemed rare in the U.S. 尽管麻疹病例呈上升趋势, 2025年11月25日报告超过1,798例, 以许多病毒使用的HSPG受体为目标的该药物的广谱设计在动物和人性化模型中显示出希望。 Despite rising measles cases, with over 1,798 reported by November 25, 2025, the drug’s broad-spectrum design, which targets HSPG receptors used by many viruses, shows promise in animal and humanized models. 在担心失去美国消除麻疹的地位的情况下,指定孤儿药品可给予长达7年的市场独家经营权,并支持发展。 Orphan drug designation could grant up to seven years of market exclusivity and support development amid concerns over losing U.S. measles elimination status.